Medtronic PLC $MDT Stake Decreased by First National Advisers LLC

First National Advisers LLC reduced its holdings in Medtronic PLC (NYSE:MDT) by 72.9% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 3,437 shares of the medical technology company’s stock after selling 9,231 shares during the quarter. First National Advisers LLC’s holdings in Medtronic were worth $327,000 at the end of the most recent quarter.

Other hedge funds have also recently added to or reduced their stakes in the company. Brighton Jones LLC lifted its stake in shares of Medtronic by 1,368.0% in the 4th quarter. Brighton Jones LLC now owns 39,989 shares of the medical technology company’s stock worth $3,194,000 after acquiring an additional 37,265 shares during the period. Sivia Capital Partners LLC increased its position in Medtronic by 9.6% in the 2nd quarter. Sivia Capital Partners LLC now owns 4,356 shares of the medical technology company’s stock worth $380,000 after purchasing an additional 381 shares during the last quarter. Kingstone Capital Partners Texas LLC bought a new stake in Medtronic in the second quarter worth $7,382,000. Perpetual Ltd lifted its holdings in Medtronic by 54.8% in the 2nd quarter. Perpetual Ltd now owns 73,624 shares of the medical technology company’s stock worth $6,418,000 after purchasing an additional 26,065 shares during the last quarter. Finally, Bell Bank bought a new stake in shares of Medtronic during the 2nd quarter worth $257,000. Institutional investors own 82.06% of the company’s stock.

Wall Street Analyst Weigh In

MDT has been the subject of a number of research reports. Daiwa Capital Markets raised their price objective on Medtronic from $104.00 to $117.00 and gave the stock a “buy” rating in a research report on Tuesday, November 25th. Leerink Partners set a $120.00 target price on shares of Medtronic and gave the company an “outperform” rating in a research note on Wednesday, November 19th. Piper Sandler reaffirmed a “neutral” rating on shares of Medtronic in a report on Monday, January 5th. Barclays lifted their price target on shares of Medtronic from $111.00 to $116.00 and gave the company an “overweight” rating in a report on Thursday, January 8th. Finally, Wall Street Zen cut shares of Medtronic from a “buy” rating to a “hold” rating in a research note on Saturday, January 3rd. One research analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and eleven have given a Hold rating to the company. According to data from MarketBeat.com, Medtronic currently has a consensus rating of “Moderate Buy” and an average target price of $110.28.

Medtronic Price Performance

MDT opened at $96.82 on Friday. The company has a debt-to-equity ratio of 0.57, a quick ratio of 1.80 and a current ratio of 2.42. Medtronic PLC has a 52 week low of $79.55 and a 52 week high of $106.33. The firm has a market capitalization of $124.12 billion, a PE ratio of 26.10, a P/E/G ratio of 2.55 and a beta of 0.71. The company has a fifty day moving average price of $98.99 and a two-hundred day moving average price of $94.88.

Medtronic (NYSE:MDT) last issued its earnings results on Tuesday, November 18th. The medical technology company reported $1.36 EPS for the quarter, beating the consensus estimate of $1.31 by $0.05. The firm had revenue of $8.96 billion during the quarter, compared to the consensus estimate of $8.86 billion. Medtronic had a net margin of 13.71% and a return on equity of 14.86%. The business’s quarterly revenue was up 6.6% on a year-over-year basis. During the same quarter in the prior year, the firm earned $1.26 earnings per share. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS. As a group, analysts anticipate that Medtronic PLC will post 5.46 earnings per share for the current year.

Medtronic Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Friday, January 16th. Shareholders of record on Friday, December 26th were paid a $0.71 dividend. The ex-dividend date of this dividend was Friday, December 26th. This represents a $2.84 dividend on an annualized basis and a yield of 2.9%. Medtronic’s payout ratio is presently 76.55%.

Medtronic Profile

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).